P Rajagopalan to Antigens, CD
This is a "connection" page, showing publications P Rajagopalan has written about Antigens, CD.
Connection Strength
0.017
-
A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant. 2007 Jul; 7(7):1770-7.
Score: 0.017